Oncotelic Therapeutics Inc. has announced the completion of a private placement, entering into subscription agreements with 21 accredited investors for the sale of 32 units as part of an offering of up to 500 units. Each unit consists of a $25,000 note bearing 12% annual interest, convertible into either 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc., a subsidiary, at $1.00 per share. Additionally, each unit includes 250,000 warrants to purchase Oncotelic common stock at $0.12 per share or 25,000 warrants for EdgePoint stock at $1.25 per share, both with anti-dilution provisions and a two-year exercise period. The offering is exempt from SEC registration under Rule 506 of Regulation D.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-029634), on December 30, 2025, and is solely responsible for the information contained therein.